{"id":408351,"date":"2021-01-05T08:03:22","date_gmt":"2021-01-05T13:03:22","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=408351"},"modified":"2021-01-05T08:03:22","modified_gmt":"2021-01-05T13:03:22","slug":"morphic-expands-research-and-development-collaboration-with-janssen-through-third-integrin-program","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/morphic-expands-research-and-development-collaboration-with-janssen-through-third-integrin-program\/","title":{"rendered":"Morphic Expands Research and Development Collaboration with Janssen Through Third Integrin Program"},"content":{"rendered":"<h2>\nNew program demonstrates breadth of MInT platform with the inclusion of activating antibodies against integrin targets<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">WALTHAM, Mass. , Jan.  05, 2021  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3XikfLZQWYIosxcxyaL0wsHS71GEfl3Gf__-rkSSzBvD3c1SWoldQsEfhD1YfNd1kVd-U-XMeSIkDHMYH0Mzbg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Morphic Therapeutic<\/a> (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today\u00a0announced the expansion of its research and development collaboration with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson. The collaboration expansion involves the initiation of work on a third integrin target, with the collaboration scope to include activating antibodies against this new target. The agreement was facilitated by Johnson &amp; Johnson Innovation.<\/p>\n<p align=\"justify\">\u201cMorphic\u2019s unique understanding of the integrin receptor enables a wide variety of therapeutic development opportunities, and we are excited to expand our outstanding collaboration with Janssen to investigate new applications of our technology to discover novel antibodies of integrins,\u201d said Bruce Rogers, Ph.D., chief scientific officer, Morphic Therapeutic. \u201cMorphic\u2019s goal is to create new integrin-targeted therapies for patients with serious diseases and we are grateful for Janssen\u2019s expertise in this mission.\u201d<\/p>\n<p align=\"justify\">Under the terms of the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lQvuBUA1C2O2ufbhIG85stMG5_wKqeWPxN-o0YyWvf5-PYUJA99OAJ3mpHwiGDu_LIm40g7Qv8hb2bD27glPVM8Rk13GHDyuQxmbYMVypRC2kul_e1rQM2hX3on7jLatlTjetAu2WmRFSPwBFOPmwol4paN_kgkLVzg2r5wL2LT0JQ5_z1pwnapz616GYeLhnsZZ1i_W9qllq4tfHywb4A==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">original<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tZouN4ATBYJ7BZgm2hyciT7CbIdjjd0UaxMH2k5TQdHGhFQnMj3ExKzhB03DN7ByQ3E1sus_NVAjY9hdxWqfR0gUd3ZYGge8rcK73RGBLPV_CBEL7cOMLXyVjzYL8YHS_gifubGwoP_nRtG7P_usq-CmzQg7B1t0PWFFZL3nHJz3ZXn4gwOs9xe44MFJiNZB25xUQIoW_3Fu8tlREy2JjAw6BqkHl-I4f5tBtQHwHNA=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"> collaboration<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=u5ahCz1y9KOiy3MkcM8XVuyYNEJSYWCXd5KdRPNZUqFpWukeFKp4N3fauODjQv1hFqDbbTSCo4ET2EiiaKqFIckUySGfJ-H2dxlu4QXrnwSa2ZGkHAiJ6q-k8LnDptixUYhBIS_7Oh3xEpSOQcVYR-6NH74CWnZt0PyMuoebaqT_KxVXfjTIdOoRwEFnALMVq6fXsFd-wbBAxZ9BIBmYxg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"> agreement<\/a>, Morphic will receive a milestone payment for initiating work on the third target. As part of the expansion any new product candidates will be subject to milestones and royalties.<\/p>\n<p align=\"justify\">\n        <strong>About Integrins<\/strong><br \/>\n        <br \/>Integrins are a ubiquitous family of receptors expressed on the surface of most human cells. Integrins are dimers comprising one \u03b1 (alpha) subunit and one \u03b2 (beta)\u00a0subunit. Integrin signaling controls a wide range of cellular processes, including cell survival, cell cycle progression, immune system activation, cell differentiation, and cell migration. Aberrant integrin signaling contributes to a diverse array of human diseases, including each of Morphic\u2019s focus areas of autoimmune diseases, fibrosis, and immuno-oncology.<\/p>\n<p align=\"justify\">\n        <strong>About Morphic Therapeutic<\/strong><br \/>\n        <br \/>Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. In collaboration with\u00a0AbbVie, Janssen and Schr\u00f6dinger,\u00a0Morphic\u00a0is advancing its pipeline and discovery activities using its proprietary Morphic Integrin Technology (MInT) Platform which leverages the Company\u2019s unique understanding of integrin structure and biology. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qe9TQgTn3wroAOtXpqscGc_RACnho6ORgiYc2mxkti-Q_p-6abMSMSDlz0DTtf3XAHsMKM5vd3UfjVq2sOnpBA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.morphic<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IjbvN2jxWhuK9JKqAv8Rb2dyxQrGpG7gnnhICYvYzjSwkTIjmn1516KkMPmdLBtYummYe6clrVhVjwV4hFst0w==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">t<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1PDTfNF9NHCi8jSLZa5koRQ7N9owY2tPXFOWZOxI-S4CDLM0OzmXeWyODhnzZtDrWER-dQYVBOzwlEoZFZulZg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">x.com<\/a>.<\/p>\n<p>\n        <strong>Cautionary Note Regarding Forward-Looking Statements<\/strong><br \/>\n        \n      <\/p>\n<p align=\"justify\">This press release contains \u201cforward-looking\u201d statements within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: Morphic\u2019s or our partners\u2019 plans or ability to develop, obtain approval for any indication or disease and\/or commercialize any oral small-molecule integrin therapeutics. Statements including words such as \u201cbelieve,\u201d \u201cplan,\u201d \u201ccontinue,\u201d \u201cexpect,\u201d \u201cwill be,\u201d \u201cdevelop,\u201d \u201csignal,\u201d \u201cpotential,\u201d \u201canticipate\u201d or \u201congoing\u201d and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause Morphic\u2019s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to Morphic\u2019s ability to develop, obtain regulatory approval for and commercialize MORF-057, MORF-720, and other product candidates, the timing and results of preclinical studies and clinical trials, the potential impact of the COVID-19 pandemic, Morphic\u2019s ability to protect intellectual property; and other risks set forth in our filings with the\u00a0Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and\u00a0Morphic\u00a0specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise, except as required by law.<\/p>\n<p align=\"left\">\n        <strong>Contacts<\/strong><br \/>\n        <br \/>Morphic Therapeutic<br \/>Chris Erdman<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Bn6L_z8eIAO5ls_qNkbZMHWt2PTb4fXw3bJbPh9_DsaRhVhobxM7PgAV6DQD5T5kdVfnbHyfFFonUzUW_5HHs8y41_Q4dQsChVV5GrFKAcwGjNC1XNxwh1TKp4UFwOTH\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">chris.erdman@morphictx.com<\/a><br \/>617.686.1718<\/p>\n<p align=\"left\">Media Contact<br \/>Adam Silverstein, Ten Bridge Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nw1m6IcyjBvCN6pvmL-KK9af_CoNgycg3e_VzDPzlQoA2BUqhPiiM_RhLHxNU7L7upCyJuIj35vFMG3jq8TAB03-_6C64053tknb8_oH57ISyTSonPda5AzYDuxj5WRU\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">adam@tenbridgecommunications.com<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ben1hvwfqwU9d0H2sNUZMBAEEwG8ceaXSbLbLmnnTqBSxiuxjxdToN64x1XTyFG2ibWEf4gQY31cMZZDmHRaDu5TkmpTnp1_m3IdvOK2230=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><br \/><\/a>917.697.9313<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDA0OCMzOTAzMTg1IzIxODc0MzU=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/c9370453-ccb1-457c-9140-a4b028b35bfc\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>New program demonstrates breadth of MInT platform with the inclusion of activating antibodies against integrin targets WALTHAM, Mass. , Jan. 05, 2021 (GLOBE NEWSWIRE) &#8212; Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today\u00a0announced the expansion of its research and development collaboration with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson. The collaboration expansion involves the initiation of work on a third integrin target, with the collaboration scope to include activating antibodies against this new target. The agreement was facilitated by Johnson &amp; Johnson Innovation. \u201cMorphic\u2019s unique understanding of the integrin receptor enables a wide variety of therapeutic development opportunities, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/morphic-expands-research-and-development-collaboration-with-janssen-through-third-integrin-program\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Morphic Expands Research and Development Collaboration with Janssen Through Third Integrin Program&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-408351","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Morphic Expands Research and Development Collaboration with Janssen Through Third Integrin Program - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/morphic-expands-research-and-development-collaboration-with-janssen-through-third-integrin-program\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Morphic Expands Research and Development Collaboration with Janssen Through Third Integrin Program - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"New program demonstrates breadth of MInT platform with the inclusion of activating antibodies against integrin targets WALTHAM, Mass. , Jan. 05, 2021 (GLOBE NEWSWIRE) &#8212; Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today\u00a0announced the expansion of its research and development collaboration with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson. The collaboration expansion involves the initiation of work on a third integrin target, with the collaboration scope to include activating antibodies against this new target. The agreement was facilitated by Johnson &amp; Johnson Innovation. \u201cMorphic\u2019s unique understanding of the integrin receptor enables a wide variety of therapeutic development opportunities, &hellip; Continue reading &quot;Morphic Expands Research and Development Collaboration with Janssen Through Third Integrin Program&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/morphic-expands-research-and-development-collaboration-with-janssen-through-third-integrin-program\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-05T13:03:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDA0OCMzOTAzMTg1IzIxODc0MzU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/morphic-expands-research-and-development-collaboration-with-janssen-through-third-integrin-program\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/morphic-expands-research-and-development-collaboration-with-janssen-through-third-integrin-program\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Morphic Expands Research and Development Collaboration with Janssen Through Third Integrin Program\",\"datePublished\":\"2021-01-05T13:03:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/morphic-expands-research-and-development-collaboration-with-janssen-through-third-integrin-program\\\/\"},\"wordCount\":649,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/morphic-expands-research-and-development-collaboration-with-janssen-through-third-integrin-program\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMDA0OCMzOTAzMTg1IzIxODc0MzU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/morphic-expands-research-and-development-collaboration-with-janssen-through-third-integrin-program\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/morphic-expands-research-and-development-collaboration-with-janssen-through-third-integrin-program\\\/\",\"name\":\"Morphic Expands Research and Development Collaboration with Janssen Through Third Integrin Program - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/morphic-expands-research-and-development-collaboration-with-janssen-through-third-integrin-program\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/morphic-expands-research-and-development-collaboration-with-janssen-through-third-integrin-program\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMDA0OCMzOTAzMTg1IzIxODc0MzU=\",\"datePublished\":\"2021-01-05T13:03:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/morphic-expands-research-and-development-collaboration-with-janssen-through-third-integrin-program\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/morphic-expands-research-and-development-collaboration-with-janssen-through-third-integrin-program\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/morphic-expands-research-and-development-collaboration-with-janssen-through-third-integrin-program\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMDA0OCMzOTAzMTg1IzIxODc0MzU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMDA0OCMzOTAzMTg1IzIxODc0MzU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/morphic-expands-research-and-development-collaboration-with-janssen-through-third-integrin-program\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Morphic Expands Research and Development Collaboration with Janssen Through Third Integrin Program\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Morphic Expands Research and Development Collaboration with Janssen Through Third Integrin Program - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/morphic-expands-research-and-development-collaboration-with-janssen-through-third-integrin-program\/","og_locale":"en_US","og_type":"article","og_title":"Morphic Expands Research and Development Collaboration with Janssen Through Third Integrin Program - Market Newsdesk","og_description":"New program demonstrates breadth of MInT platform with the inclusion of activating antibodies against integrin targets WALTHAM, Mass. , Jan. 05, 2021 (GLOBE NEWSWIRE) &#8212; Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today\u00a0announced the expansion of its research and development collaboration with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson. The collaboration expansion involves the initiation of work on a third integrin target, with the collaboration scope to include activating antibodies against this new target. The agreement was facilitated by Johnson &amp; Johnson Innovation. \u201cMorphic\u2019s unique understanding of the integrin receptor enables a wide variety of therapeutic development opportunities, &hellip; Continue reading \"Morphic Expands Research and Development Collaboration with Janssen Through Third Integrin Program\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/morphic-expands-research-and-development-collaboration-with-janssen-through-third-integrin-program\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-05T13:03:22+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDA0OCMzOTAzMTg1IzIxODc0MzU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/morphic-expands-research-and-development-collaboration-with-janssen-through-third-integrin-program\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/morphic-expands-research-and-development-collaboration-with-janssen-through-third-integrin-program\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Morphic Expands Research and Development Collaboration with Janssen Through Third Integrin Program","datePublished":"2021-01-05T13:03:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/morphic-expands-research-and-development-collaboration-with-janssen-through-third-integrin-program\/"},"wordCount":649,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/morphic-expands-research-and-development-collaboration-with-janssen-through-third-integrin-program\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDA0OCMzOTAzMTg1IzIxODc0MzU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/morphic-expands-research-and-development-collaboration-with-janssen-through-third-integrin-program\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/morphic-expands-research-and-development-collaboration-with-janssen-through-third-integrin-program\/","name":"Morphic Expands Research and Development Collaboration with Janssen Through Third Integrin Program - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/morphic-expands-research-and-development-collaboration-with-janssen-through-third-integrin-program\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/morphic-expands-research-and-development-collaboration-with-janssen-through-third-integrin-program\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDA0OCMzOTAzMTg1IzIxODc0MzU=","datePublished":"2021-01-05T13:03:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/morphic-expands-research-and-development-collaboration-with-janssen-through-third-integrin-program\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/morphic-expands-research-and-development-collaboration-with-janssen-through-third-integrin-program\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/morphic-expands-research-and-development-collaboration-with-janssen-through-third-integrin-program\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDA0OCMzOTAzMTg1IzIxODc0MzU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDA0OCMzOTAzMTg1IzIxODc0MzU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/morphic-expands-research-and-development-collaboration-with-janssen-through-third-integrin-program\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Morphic Expands Research and Development Collaboration with Janssen Through Third Integrin Program"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/408351","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=408351"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/408351\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=408351"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=408351"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=408351"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}